Aldeyra Therapeutics マネジメント

マネジメント基準チェック /24

Aldeyra Therapeuticsの CEO はTodd Bradyで、 Jan2012年に任命され、の在任期間は 12.83年です。の年間総報酬は$ 3.68Mで、 15.8%給与と84.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.94%を直接所有しており、その価値は$ 5.71M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と11.3年です。

主要情報

Todd Brady

最高経営責任者

US$3.7m

報酬総額

CEO給与比率	15.8%
CEO在任期間	12.8yrs
CEOの所有権	1.9%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	11.3yrs

経営陣の近況

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

CEO報酬分析

Aldeyra Therapeutics の収益と比較して、Todd Brady の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$4m	US$581k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$3m	US$559k	-US$62m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$3m	US$547k	-US$58m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$2m	US$544k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$49m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$4m	US$523k	-US$61m
Sep 30 2019	n/a	n/a	-US$58m
Jun 30 2019	n/a	n/a	-US$50m
Mar 31 2019	n/a	n/a	-US$46m
Dec 31 2018	US$3m	US$506k	-US$39m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$29m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$2m	US$473k	-US$22m

報酬と市場: Toddの総報酬 ($USD 3.68M ) は、 US市場 ($USD 1.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Toddの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Todd Brady (52 yo)

12.8yrs

在職期間

US$3,684,651

報酬

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Todd Brady	CEO, President & Director	12.8yrs	US$3.68m	1.94% $ 5.7m
Stephen Machatha	Chief Development Officer	3.8yrs	US$1.59m	0.19% $ 552.1k
Michael Alfieri	Principal Financial & Accounting Officer	less than a year	データなし	データなし
David Burke	Head of Investor Relations	no data	データなし	データなし
Laura Nichols	Operations Manager	no data	データなし	データなし

3.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: ALDXの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Todd Brady	CEO, President & Director	19.8yrs	US$3.68m	1.94% $ 5.7m
Richard Douglas	Independent Chair of the Board	8.2yrs	US$221.98k	0.21% $ 617.5k
Ben Bronstein	Independent Director	14.4yrs	US$190.40k	0.047% $ 139.6k
Gary Phillips	Independent Director	15.5yrs	US$194.07k	0.025% $ 73.2k
Martin Joyce	Independent Director	11.1yrs	US$195.66k	0.040% $ 118.4k
Neal Walker	Independent Director	11.4yrs	US$174.22k	0.027% $ 78.3k
Jay Duker	Member of Retina Segment Scientific Advisory Board	no data	データなし	データなし
Paul Karpecki	Member of Anterior Segment Scientific Advisory Board	4.8yrs	データなし	データなし
John Sheppard	Member of Anterior Segment Scientific Advisory Board	no data	データなし	データなし
Nancy Miller-Rich	Independent Director	4.8yrs	US$174.22k	0% $ 0
Victor Perez	Member of Anterior Segment Scientific Advisory Board	no data	データなし	データなし
David Chu	Member of Anterior Segment Scientific Advisory Board	no data	データなし	データなし

11.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: ALDXの取締役会は経験豊富で経験豊富です ( 11.3年の平均在任期間)。

Aldeyra Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$492k worth of stock

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

マネジメント基準チェック /24